Pacific Edge now has several US contracts in place, and its suite of CX-bladder diagnostic and management tools are being tested in several ''user programmes'', which can ultimately lead to more contracts.
Across several US contracts, its potential customer base now numbers in the tens of millions, which include contracts with the Veterans Association, Kaiser Permanante, Centres for Medicare and Medicaid Services.
The new US contract is with MediNcrease Health Plan, a national provider network which would make CX-bladder available to its 5.5 million clients and payers.
The company's shares rose 3.8% to 41c following the announcement.
Pacific Edge chief executive David Darling said the MediNcrease agreement reflected the growing acceptance of CX-bladder as a highly accurate, non-invasive test for detecting and managing urothelial cancer.
''Having commercial agreements in place with provider networks is an important part of reimbursement of CX-bladder in the US, minimising barriers for urologists who order CX-bladder tests for their patient care,'' Mr Darling said.
MediNcrease's US client base includes regional and national health plans, insurance companies, employers, municipalities, third-party administrators, unions and other companies.
